Umer: Listing data to copy and paste in each doctor’s listing

Mercy Medical Group: Dr. Rubina Inamdar and Dr. Binita Mandal

Windom Allergy: Dr. Hugh Windom and Dr. Jean Ly

Kansas City Allergy and Asthma: Dr. Derrick Ward, Dr. James Sterner and  Dr. Mark Neustrom

Allergy, Asthma & Sinus Care Center: Dr. Manoj Warrier and Dr. Josie Vitale

Bernstein Allergy: Dr. Jonathan Bernstein and Dr. Justin Greiwe

New England Food Allergy Treatment Center (NEFATC): Dr. Jeffrey Factor, Dr. Jason Lee and Dr. Louis Mendelson

North Texas Allergy & Asthma Center: Dr. Roshni Kandyil Foster, Dr. Samuel Foster and Dr. B.A. Badie

Allergy and Asthma Specialists Ltd: Dr. Gary Moss, Dr. Craig Koenig and Dr. Gregory Pendell

Food Allergy Institute of North Texas: Dr. Mary Hudelson, Dr. Erin Clarke, Dr. Marie Fitzgerald

DallasAllergyImmunology / Allergy Partners of North Texas: Dr. Richard Wasserman, Dr. Robert Sugerman, Dr. Qurat Kamili

 

National Institute of Health: “Oral Immunotherapy Is Safe, Effective Treatment for Peanut-Allergic Preschoolers”

NIH NIAIDFor Immediate Release: Wednesday, Aug. 10, 2016

Oral Immunotherapy Is Safe, Effective Treatment for Peanut-Allergic Preschoolers, Study Suggests

WHAT:
Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found. Peanut OIT involves eating small, gradually increasing amounts of peanut protein daily. Low-dose and high-dose OIT were safe and equally effective at suppressing allergic immune responses to peanut, investigators found. The work was partly supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Center for Advancing Translational Sciences, both part of the National Institutes of Health.

Previous studies with older children showed that peanut OIT can offer some protection against potentially life-threatening anaphylaxis caused by peanut exposure. In this study, researchers led by Wesley Burks, M.D., of the University of North Carolina at Chapel Hill, assessed whether giving OIT to younger children whose duration of peanut allergy was short could alter the course of the allergy and allow safe introduction of peanut into the diet.

peanut quote thumbnail

The study team enrolled 40 peanut-allergic children aged 9 to 36 months. They randomly assigned participants to either high-dose peanut OIT with a target daily dose of 3,000 milligrams peanut protein or a low-dose regimen with a target dose of 300 milligrams. Nearly all participants experienced some side effects, such as abdominal pain, but these were generally mild, and required little or no treatment. After receiving OIT for 29 months on average, participants avoided peanut completely for four weeks before attempting to reintroduce it into their diets.

Almost 80 percent of participants successfully reintroduced peanut with no allergic response, with no significant differences between the low-dose and high-dose arms. Comparison of the OIT-treated children with a control group of 154 peanut-allergic children who had avoided peanut showed that OIT-treated children were 19 times more likely to successfully incorporate peanut into their diets. The investigators are continuing to monitor the OIT-treated participants to assess the long-term treatment outcomes.
Currently, the NIAID-supported Immune Tolerance Network is conducting a randomized trial called IMPACT to determine whether peanut OIT can lower the risk of allergic reactions, induce tolerance and change the immune responses of peanut-allergic children aged 12 to 48 months.

ARTICLE:
BP Vickery et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. Journal of Allergy and Clinical Immunology DOI: 10.1016/j.jaci.2016.05.027  (2016).
WHO:
Marshall Plaut, M.D., chief of the Food Allergy, Atopic Dermatitis and Allergic Mechanisms Section in NIAID’s Division of Allergy, Immunology and Transplantation, is available to discuss the findings.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health ®

Read the whole article here: http://www.niaid.nih.gov/news/newsreleases/2016/Pages/peanut-OIT.aspx

 

 

Site created by Food Allergy Parents like YOU ! … They said there were NO TREATMENTS for food allergy!